| Outcome Measures: |
Primary: Number of participants with treatment emergent adverse event (TEAEs), From first study intervention administration until [including] 7 days after end of treatment with study intervention (approximately 25 days)|Percentage of participants with treatment emergent adverse event (TEAEs), From first study intervention administration until [including] 7 days after end of treatment with study intervention (approximately 25 days) | Secondary: AUC of BAY3283142, AUC: Area under the concentration vs. Time curve from zero to infinity after single (first) dose, 0 to 48 hours post-dose after the first dose on Day 1|Cmax of BAY3283142, Cmax: Maximum observed drug concentration in measured matrix after single dose administration, directly taken from analytical data, 0 to 48 hours post-dose after the first dose on Day 1|AUC/D of BAY3283142, AUC/D: AUC divided by dose, 0 to 48 hours post-dose after the first dose on Day 1|Cmax/D of BAY3283142, Cmax/D: Cmax devided by dose, 0 to 48 hours post-dose after the first dose on Day 1|AUCτ,md of BAY3283142, AUCτ,md: AUC during any dose interval after multiple dose, 0 to 24 hours post-dose after the last dose on Day 9|Cmax,md of BAY3283142, Cmax,md: Maximum observed drug concentration in measured matrix after multiple dose administration during a dosage interval, directly taken from analytical data, 0 to 24 hours post-dose after the last dose on Day 9|AUCτ,md/D of BAY3283142, AUCτ,md/D: AUC during any dose interval after multiple dose divided by dose, 0 to 24 hours post-dose after the last dose on Day 9|Cmax,md/D of BAY3283142, Cmax,md/D: Cmax,md divided by dose, 0 to 24 hours post-dose after the last dose on Day 9
|
